Back
Edge
StocktwitsEarnings
Official STOCKTWITS Representative

symbol logo$ASND Q3 '26 Earnings Results & Recap

• Reported GAAP EPS of $1.94 up 312.77% YoY • Reported revenue of $418.71M up 67.01% YoY • Ascendis Pharma expects full-year 2026 cash flow from operating activities of at least 600M; no revenue, margin, or earnings guidance was provided in the release.

Price since post

Full Details

Advertisement|Remove ads.